



November 9 2020  
Hisamitsu Pharmaceutical Co., Inc.

**Notification of Voluntary Recall for Overseas Pharmaceutical Drug**  
**“SALONPAS®” (2 Patches)**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu, Saga, Japan; President and CEO: Kazuhide Nakatomi, hereinafter referred to as “Hisamitsu Pharmaceutical”) is voluntarily recalling the relevant lots of analgesic anti-inflammatory drug “SALONPAS®” (2 Patches) (hereinafter referred to as “This Drug”) which the active ingredient of methyl salicylate were found to be below the content standard from the stability monitoring test. We will implement the recall appropriately by consulting regulatory authorities of each overseas export destination countries.

Furthermore, although there may have lack of efficacy due to the decrease in content, there is no risk of potential serious health hazard due to this event. Presently, there have been no reports of health hazard resulting from this event.

This Drug is for overseas export only and not distributed in Japan.

We deeply apologize for any inconvenience and concerns this may cause our customer and business partners. We will take steps to prevent any reoccurrence, placing further emphasis on quality control of our products.

**Contact Information**

2-4-1 Marunouchi, Chiyoda-ku, Tokyo 100-6330  
+81-3-5293-1720 (From Overseas)